Sun Pharmaceutical Industries has reported results for the second quarter ended September 30, 2013.
The company has reported a fall of 98.30% in its net profit of Rs 6.30 crore for the quarter as compared to Rs 370.62 crore for the same quarter in the previous year. Total income of the company has decreased by 44.02% at Rs 643.74 crore for quarter under review as compared to Rs 1149.93 crore for the quarter ended September 30, 2012.
On the consolidated basis, the group has reported over 4 fold jump in net profit after taxes, minority interest and share of profit / (loss) of associates at Rs 1362.30 crore as compared to Rs 319.64 crore in the same quarter previous year. Total income of the group rose 52.19% to Rs 4311.63 crore for quarter under review as against Rs 2833.13 crore in corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: